BRAF and MEK inhibitor therapy eliminates nestin expressing melanoma cells in human tumors Experiment 2 ( Melanoma Panel 3.0 Patients Melanoma Cells)

To provide single-cell mass cytometry data of melanoma treatment response after dabrafenib and trametinib therapy. This panel dissects melanoma cancer cell heterogeneity to identify subset phenotypes that escape therapy. This data specifically looks at pre-gated melanoma cancer cells only before and after 4 weeks of targeted therapy (dabrafenib and trametinib).
Conclusion:
Cellular heterogeneity was different between patients tumors. Some patients exhibited the emergence of novel subset phenotypes that did not exist before therapy, or persistence of stable subset phenotypes. Furthermore, across all patients, we observed the loss of nestin-expressing melanoma cells after therapy and the persistence of MHC I low/negative subset phenotypes.
Notes:
This data specifically looks at pre-gated melanoma cancer cells only before and after 4 weeks of targeted therapy (dabrafenib and trametinib).This data is shown in Figure 3, Figure 4, Supplementary Figure S4, Supplementary Figure S5, and Supplementary Figure S6. These events are intact cells pre-gated with histone H3 and rhodium intercalator as a viability agent. Fluidigm bead-based normalization was performed before analysis and beads were removed before viSNE analysis.